Microarray analysis of differentially regulated genes in human neuronal and epithelial cell lines upon exposure to type A botulinum neurotoxin

Biochemical and Biophysical Research Communications

Volumn 405, Issue 4, 2011, Pages 684-690

  Thirunavukkarasusx, Nagarajan ^a   Ghosal, Koyel J ^a   Kukreja, Roshan ^a   Zhou, Yu ^a   Dombkowski, Alan ^b   Cai, Shuowei ^a   Singh, Bal Ram ^a  

^a UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Botulinum neurotoxin; Botulism; Host cell response; HT 29 epithelial; Microarray; SH SY5Y neuroblastoma

Indexed keywords

BOTULINUM TOXIN A; CALCIUM; CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL; PROTEASOME; UBIQUITIN;

ARTICLE; CALCIUM SIGNALING; CANCER CELL CULTURE; CELL ADHESION; CELL JUNCTION; CELL LEVEL; COLON CARCINOMA; CONTROLLED STUDY; EPITHELIUM; FOCAL ADHESION; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MICROARRAY ANALYSIS; NERVE CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION;

BOTULINUM TOXINS, TYPE A; GENE EXPRESSION; GENE EXPRESSION REGULATION; HT29 CELLS; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; NEURONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 79951943486     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.01.102     Document Type: Article

References (37)

1. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80:717-766.
2. Sakaguchi G. Clostridium botulinum toxins. Pharmacol. Ther. 1982, 19:165-194.
3. Schantz E.J., Johnson E.A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev. 1992, 56:80-99.
4. Poulain B., Popoff M.R., Molgo J. How do the botulinum neurotoxins block the neurotransmitter release: from botulism to the molecular mechanism of action. TBJ 2008, 1:14-87.
5. Fujinaga Y., Inoue K., Watanabe S., Yokota K., Hirai Y., Nagamachi E., Oguma K. The haemagglutinin of Clostridium botulinum type C progenitor toxin plays an essential role in binding of toxin to the epithelial cells of guinea pig small intestine, leading to the efficient absorption of the toxin. Microbiology 1997, 143(Pt 12):3841-3847.
6. Fujinaga Y., Inoue K., Nomura T., Sasaki J., Marvaud J.C., Popoff M.R., Kozaki S., Oguma K. Identification, characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes. FEBS Lett. 2000, 467:179-183.
7. Fujinaga Y., Inoue K., Watarai S., Sakaguchi Y., Arimitsu H., Lee J.C., Jin Y., Matsumura T., Kabumoto Y., Watanabe T., Ohyama T., Nishikawa A., Oguma K. Molecular characterization of binding subcomponents of Clostridium botulinum type C progenitor toxin for intestinal epithelial cells and erythrocytes. Microbiology 2004, 150:1529-1538.
8. Y. Fujinaga, Interaction of botulinum toxin with the epithelial barrier, J. Biomed. Biotechnol. (2010) ID: 974943.
9. Matsumura T., Jin Y., Kabumoto Y., Takegahara Y., Oguma K., Lencer W.I., Fujinaga Y. The HA proteins of botulinum toxin disrupt intestinal epithelial intercellular junctions to increase toxin absorption. Cell. Microbiol. 2008, 10:355-364.
10. Jin Y., Takegahara Y., Sugawara Y., Matsumura T., Fujinaga Y. Disruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins - differences in cell tropism and the mechanism of action between HA proteins of types A or B and HA proteins of type C. Microbiology 2009, 155:35-45.
11. Sugawara Y., Matsumura T., Takegahara Y., Jin Y., Tsukasaki Y., Takeichi M., Fujinaga Y. Botulinum hemagglutinin disrupts the intercellular epithelial barrier by directly binding E-cadherin,. J. Cell Biol. 2010, 189:691-700.
12. Sharma S.K., Singh B.R. Enhancement of the endopeptidase activity of purified botulinum neurotoxins A, E by an isolated component of the native neurotoxin associated proteins. Biochemistry 2004, 43:4791-4798.
13. Caya J.G., Agni R., Miller J.E. Clostridium botulinum and the clinical laboratorian: a detailed review of botulism, including biological warfare ramifications of botulinum toxin. Arch. Pathol. Lab. Med. 2004, 128:653-662.
14. Rohrich R.J., Janis J.E., Fagien S., Stuzin J.M. Botulinum toxin: expanding role in medicine. Plast. Reconstr. Surg. 2003, 112:1S-3S.
15. Salti G., Ghersetich I. Advanced botulinum toxin techniques against wrinkles in the upper face. Clin. Dermatol. 2008, 26:182-191.
16. Rinaldi A. Healing Beauty? more biotechnology cosmetic products that claim drug-like properties reach the market. EMBO Rep. 2008, 9:1073-1077.
17. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., Lempicki R.A. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 2003, 4:P3.
18. Purkiss J.R., Friis L.M., Doward S., Quinn C.P. Clostridium botulinum neurotoxins act with a wide range of potencies on SH-SY5Y human neuroblastoma cells. Neurotoxicology 2001, 22:447-453.
19. Nishikawa A., Uotsu N., Arimitsu H., Lee J.C., Miura Y., Fujinaga Y., Nakada H., Watanabe T., Ohyama T., Sakano Y., Oguma K. The receptor and transporter for internalization of Clostridium botulinum type C progenitor toxin into HT-29 cells. Biochem. Biophys. Res. Commun. 2004, 319:327-333.
20. Ge S., Song L., Serwanski D.R., Kuziel W.A., Pachter J.S. Transcellular transport of CCL2 across brain microvascular endothelial cells. J. Neurochem. 2008, 104:1219-1232.
21. Verderio C., Grumelli C., Raiteri L., Coco S., Paluzzi S., Caccin P., Rossetto O., Bonanno G., Montecucco C., Matteoli M. Traffic of botulinum toxins A, E in excitatory, inhibitory neurons. Traffic 2007, 8:142-153.
22. Fourgeaud L., Boulanger L.M. Synapse remodeling, compliments of the complement system. Cell 2007, 131:1034-1036.
23. Osborne S.L., Meunier F.A., Schiavo G. Phosphoinositides as key regulators of synaptic function. Neuron 2001, 32:9-12.
24. Ishida H., Zhang X., Erickson K., Ray P. Botulinum toxin type A targets RhoB to inhibit lysophosphatidic acid-stimulated actin reorganization and acetylcholine release in nerve growth factor-treated PC12 cells. J. Pharmacol. Exp. Ther. 2004, 310:881-889.
25. Coffield J.A., Yan X. Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons. J. Pharmacol. Exp. Ther. 2009, 330:352-358.
26. Ooms L.M., Fedele C.G., Astle M.V., Ivetac I., Cheung V., Pearson R.B., Layton M.J., Forrai A., Nandurkar H.H., Mitchell C.A. The inositol polyphosphate 5-phosphatase, PIPP, is a novel regulator of phosphoinositide 3-kinase-dependent neurite elongation. Mol. Biol. Cell 2006, 17:607-622.
27. Rogozhin A.A., Pang K.K., Bukharaeva E., Young C., Slater C.R. Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A. J. Physiol. 2008, 586:3163-3182.
28. Duke D.C., Moran L.B., Kalaitzakis M.E., Deprez M., Dexter D.T., Pearce R.K., Graeber M.B. Transcriptome analysis reveals link between proteasomal, mitochondrial pathways in Parkinson's disease. Neurogenetics 2006, 7:139-148.
29. Tsai Y.C., Maditz R., Kuo C.L., Fishman P.S., Shoemaker C.B., Oyler G.A., Weissman A.M. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc. Natl. Acad. Sci. USA 2010, 107:16554-16559.
30. Maksymowych A.B., Simpson L.L. Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells. J. Biol. Chem. 1998, 273:21950-21957.
31. Maksymowych A.B., Simpson L.L. Structural features of the botulinum neurotoxin molecule that govern binding and transcytosis across polarized human intestinal epithelial cells. J. Pharmacol. Exp. Ther. 2004, 310:633-641.
32. Inoue K., Fujinaga Y., Honke K., Arimitsu H., Mahmut N., Sakaguchi Y., Ohyama T., Watanabe T., Inoue K., Oguma K. Clostridium botulinum type A haemagglutinin-positive progenitor toxin (HA(+)-PTX) binds to oligosaccharides containing gal beta1-4GlcNAc through one subcomponent of haemagglutinin (HA1). Microbiology 2001, 147:811-819.
33. Maksymowych A.B., Reinhard M., Malizio C.J., Goodnough M.C., Johnson E.A., Simpson L.L. Pure botulinum neurotoxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade. Infect. Immun. 1999, 67:4708-4712.
34. Ahsan C.R., Hajnoczky G., Maksymowych A.B., Simpson L.L. Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells. J. Pharmacol. Exp. Ther. 2005, 315:1028-1035.
35. Couesnon A., Shimizu T., Popoff M.R. Differential entry of botulinum neurotoxin A into neuronal and intestinal cells. Cell. Microbiol. 2009, 11:289-308.
36. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312:592-596.
37. Zhou Y., Foss S., Lindo P., Sarkar H., Singh B.R. Hemagglutinin-33 of type A botulinum neurotoxin complex binds with synaptotagmin II. FEBS J. 2005, 272:2717-2726.